Genfit S.A.

EPA:GNFT.PA

3.95 (EUR) • At close September 18, 2024
Bedrijfsnaam Genfit S.A.
Symbool GNFT.PA
Munteenheid EUR
Prijs 3.95
Beurswaarde 196,675,193
Dividendpercentage 0%
52-weken bereik 2.84 - 5.79
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jean-Francois Mouney
Website https://www.genfit.com

An error occurred while fetching data.

Over Genfit S.A.

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of

Vergelijkbare Aandelen

Nanobiotix S.A. logo

Nanobiotix S.A.

NANO.PA

4.454 EUR

Median Technologies SA logo

Median Technologies SA

ALMDT.PA

4.07 EUR

Cellectis S.A. logo

Cellectis S.A.

ALCLS.PA

2.065 EUR

DBV Technologies S.A. logo

DBV Technologies S.A.

DBV.PA

2.136 EUR

Malin Corporation plc logo

Malin Corporation plc

MLC.IR

6.1 EUR

MedinCell S.A. logo

MedinCell S.A.

MEDCL.PA

16.3 EUR

UG Healthcare Corporation Limited logo

UG Healthcare Corporation Limited

8K7.SI

0.128 SGD

Biosynex SA logo

Biosynex SA

ALBIO.PA

4.335 EUR

Amplitude Surgical SA logo

Amplitude Surgical SA

AMPLI.PA

3.42 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)